Midostaurin, an orally administered multi-kinase/FLT3-/KIT-inhibitor improves survival in FLT3pos AML and achieves overall response rates of 60% in patients with advSM [46, 47]. This evidence concerns the gene KIT and acute myeloid leukemia.